Financial Trends -- 6.0/10
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Sales | DKK 126,946M | DKK 140,800M | DKK 176,954M | DKK 232,261M | DKK 290,403M | DKK 309,064M |
| YoY Growth | — | +10.9% | +25.7% | +31.2% | +25.0% | +6.4% |
| Gross Profit | DKK 106,014M | DKK 117,142M | DKK 148,506M | DKK 196,496M | DKK 245,881M | DKK 250,276M |
| Gross Margin | 83.5% | 83.2% | 83.9% | 84.6% | 84.7% | 81.0% |
| Operating Profit | DKK 54,126M | DKK 58,644M | DKK 74,809M | DKK 102,574M | DKK 128,339M | DKK 127,658M |
| Op Margin | 42.6% | 41.6% | 42.3% | 44.2% | 44.2% | 41.3% |
| EBITDA | — | — | DKK 82,171M | DKK 111,987M | DKK 147,446M | DKK 149,640M |
| Free Cash Flow | DKK 28,565M | DKK 29,319M | DKK 57,362M | DKK 68,326M | (DKK 14,707M) | DKK 28,295M |
| Diluted EPS (DKK) | DKK 18.01 | DKK 20.74 | DKK 24.44 | DKK 18.62 | DKK 22.63 | DKK 23.03 |
| Avg Diluted Shares (M) | — | — | — | 4,495M | 4,463M | 4,448M |
- Revenue deceleration is severe: Growth went from +31.2% in 2023 to +25.0% in 2024 to just +6.4% in 2025. 2026 guidance is -5% to -13% CER -- the first-ever negative guidance in NVO history
- Gross margin contracted 370bps: From 84.7% (2024) to 81.0% (2025), driven by Catalent depreciation and amortization, manufacturing restructuring, and pricing pressure from MFN and self-pay channels
- Operating margin declined 290bps: From 44.2% to 41.3%, with SG&A spending on Wegovy launches and R&D investment compressing profitability further
- FCF remains impaired: 2024 was negative (DKK -14.7B) due to Catalent acquisition. 2025 recovered to DKK 28.3B but remains well below the 2022-2023 peak of DKK 57-68B. 2026 guided DKK 35-45B with DKK 55B capex
- EPS growth has stalled: DKK 23.03 in 2025 vs DKK 22.63 in 2024 (+1.8%) -- virtually flat despite a mild share count tailwind
| Metric | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | DKK 53,367M | DKK 54,300M | DKK 58,731M | DKK 65,863M | DKK 65,349M | DKK 68,060M | DKK 71,311M | DKK 85,683M | DKK 78,087M | DKK 76,857M | DKK 74,976M | DKK 79,144M |
| YoY Growth | — | — | — | — | +22.5% | +25.3% | +21.4% | +30.1% | +19.5% | +12.9% | +5.1% | -7.6% |
| Gross Margin | 84.7% | 85.5% | 83.5% | 84.8% | 84.8% | 84.9% | 84.1% | 84.8% | 83.5% | 83.3% | 76.1% | 80.9% |
| Op Margin | 46.9% | 44.0% | 45.8% | 40.6% | 48.7% | 38.1% | 47.4% | 42.9% | 49.7% | 43.5% | 31.6% | 40.1% |
| Free Cash Flow | DKK 24,764M | DKK 20,773M | DKK 30,039M | (DKK 7,250M) | DKK 5,020M | DKK 36,289M | DKK 30,451M | (DKK 86,467M) | DKK 9,492M | DKK 24,079M | DKK 30,316M | (DKK 35,592M) |
- Q4 2025 was the first YoY revenue decline at -7.6%: Revenue of DKK 79.1B vs DKK 85.7B in Q4 2024. The deceleration arc from +30.1% (Q4 24) to -7.6% (Q4 25) took just four quarters
- Gross margin hit a trough of 76.1% in Q3 2025: A 870bp decline from Q3 2024 (84.1%), reflecting Catalent integration costs and restructuring charges. Q4 2025 recovered to 80.9%
- Operating margin collapsed to 31.6% in Q3 2025: Down from 47.4% a year prior, the worst quarterly op margin in years. Reflects both cost absorption and one-time charges
- FCF is highly lumpy: Q4 quarters consistently show large negative FCF (Q4 2023: -7.3B, Q4 2024: -86.5B from Catalent, Q4 2025: -35.6B from capex timing). This pattern obscures underlying cash generation
- The deceleration trend is unmistakable: YoY revenue growth went +22.5%, +25.3%, +21.4%, +30.1%, +19.5%, +12.9%, +5.1%, -7.6% over eight sequential quarters
NVO was one of the fastest-growing large-cap pharma companies in history from 2021-2024, with revenue accelerating from +10.9% to +31.2% on the back of the GLP-1 revolution. That growth engine has now stalled dramatically. FY2025 revenue growth of +6.4% represents a sharp deceleration, and Q4 2025 posted the first YoY decline at -7.6%. The 2026 guidance of -5% to -13% CER confirms this is not a one-quarter blip but a structural shift driven by pricing concessions (MFN deal, $245/mo Medicare, $199 self-pay) and intensifying competition from Eli Lilly.
Margins are compressing across the board. Gross margin fell 370bps to 81.0% in 2025, operating margin dropped 290bps to 41.3%, and Q3 2025 saw a trough operating margin of just 31.6%. The Catalent acquisition added manufacturing capacity but also significant depreciation and integration costs that are pressuring profitability.
FCF was negative in 2024 (DKK -14.7B) due to the Catalent deal and partially recovered in 2025 (DKK 28.3B), but remains well below the 2022-2023 peak of DKK 57-68B. With DKK 55B in capex guided for 2026, the FCF trajectory remains constrained.
EPS growth has effectively stalled at DKK 23.03 (+1.8% YoY), with mild share buybacks providing the only tailwind. The company has gone from a hyper-growth profile to a decelerating, margin- compressing story in the span of two years.
Penalty modifiers applied: -2 for negative FCF year (2024FY).
Score: 6.0/10 -- Base of ~8 for historically strong revenue acceleration (2021-2024), minus 2 for the negative FCF year, with additional deductions for margin compression, forward negative guidance, and EPS stagnation. The deceleration from +31% to -7.6% quarterly growth in under two years is among the sharpest for a mega-cap pharma company.